Annotation Detail
Information
- Associated Genes
- KIT
- Associated Variants
-
KIT EXON 9 MUTATION
KIT EXON 9 MUTATION - Associated Disease
- gastrointestinal stromal tumor
- Source Database
- CIViC Evidence
- Description
- This phase II clinical trial of regorafenib (NCT01068769) examined the long term safety and efficacy of regorafenib monotherapy in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) who failed previous treatments with imatinib. In response to regorafenib monotherapy, patients whose GISTs harbored KIT exon 9 mutations experienced lower rates of clinical benefit (defined as complete response, partial response, or stable disease lasting >16 weeks) than patients whose GISTs harbored KIT exon 11 mutations or KIT/PDGFR wildtype SDH-deficient patients. Of 3 patients with KIT exon 9 mutant GISTs, 2 experienced clinical benefit (including one PR), and the median progression free survival was 5.7 months.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/4104
- Gene URL
- https://civic.genome.wustl.edu/links/genes/29
- Variant URL
- https://civic.genome.wustl.edu/links/variants/509
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Gastrointestinal Stromal Tumor
- Evidence Direction
- Supports
- Drug
- Regorafenib
- Evidence Level
- C
- Clinical Significance
- Reduced Sensitivity
- Pubmed
- 27371698
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Regorafenib | N/A | true |